Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal

[cafead]

via Swiss biopharma Roche is betting more than $1 billion that Sarepta Therapeutics, which recently won FDA approval for its second RNA medicine for Duchenne muscular dystrophy, will get its lead gene therapy treatment across the finish line too.

article source